Methotrexate in advanced endometrial carcinoma. A Phase II trial of the Gynecologic Oncology Group

H. B. Muss, J. A. Blessing, Kenneth D Hatch, J. T. Soper, K. D. Webster, G. M. Kemp

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Thirty-three patients with advanced or metastatic endometrial carcinoma were entered in a Phase II trial utilizing methotrexate, 40 mg/m2 intravenously on a weekly basis. Almost all patients had prior total abdominal hysterectomy and almost two-thirds prior pelvic irradiation. No patient had prior chemotherapy. There was one complete and one partial response, for a complete and partial response rate of 6% (95% confidence intervals for a response of 1.7 to 19.6%). Toxicity was mild, with major adverse effects being nausea and vomiting and myelosuppression. One death may have been drug related. Methotrexate displays minimal clinical activity in patients with advanced or recurrent endometrial carcinoma who have received no prior chemotherapy.

Original languageEnglish (US)
Pages (from-to)61-63
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number1
StatePublished - 1990
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Methotrexate
Drug Therapy
Hysterectomy
Nausea
Vomiting
Confidence Intervals
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Methotrexate in advanced endometrial carcinoma. A Phase II trial of the Gynecologic Oncology Group. / Muss, H. B.; Blessing, J. A.; Hatch, Kenneth D; Soper, J. T.; Webster, K. D.; Kemp, G. M.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, No. 1, 1990, p. 61-63.

Research output: Contribution to journalArticle

Muss, H. B. ; Blessing, J. A. ; Hatch, Kenneth D ; Soper, J. T. ; Webster, K. D. ; Kemp, G. M. / Methotrexate in advanced endometrial carcinoma. A Phase II trial of the Gynecologic Oncology Group. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1990 ; Vol. 13, No. 1. pp. 61-63.
@article{717d9e9e956e4cfab3a2a951d4ad2b26,
title = "Methotrexate in advanced endometrial carcinoma. A Phase II trial of the Gynecologic Oncology Group",
abstract = "Thirty-three patients with advanced or metastatic endometrial carcinoma were entered in a Phase II trial utilizing methotrexate, 40 mg/m2 intravenously on a weekly basis. Almost all patients had prior total abdominal hysterectomy and almost two-thirds prior pelvic irradiation. No patient had prior chemotherapy. There was one complete and one partial response, for a complete and partial response rate of 6{\%} (95{\%} confidence intervals for a response of 1.7 to 19.6{\%}). Toxicity was mild, with major adverse effects being nausea and vomiting and myelosuppression. One death may have been drug related. Methotrexate displays minimal clinical activity in patients with advanced or recurrent endometrial carcinoma who have received no prior chemotherapy.",
author = "Muss, {H. B.} and Blessing, {J. A.} and Hatch, {Kenneth D} and Soper, {J. T.} and Webster, {K. D.} and Kemp, {G. M.}",
year = "1990",
language = "English (US)",
volume = "13",
pages = "61--63",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Methotrexate in advanced endometrial carcinoma. A Phase II trial of the Gynecologic Oncology Group

AU - Muss, H. B.

AU - Blessing, J. A.

AU - Hatch, Kenneth D

AU - Soper, J. T.

AU - Webster, K. D.

AU - Kemp, G. M.

PY - 1990

Y1 - 1990

N2 - Thirty-three patients with advanced or metastatic endometrial carcinoma were entered in a Phase II trial utilizing methotrexate, 40 mg/m2 intravenously on a weekly basis. Almost all patients had prior total abdominal hysterectomy and almost two-thirds prior pelvic irradiation. No patient had prior chemotherapy. There was one complete and one partial response, for a complete and partial response rate of 6% (95% confidence intervals for a response of 1.7 to 19.6%). Toxicity was mild, with major adverse effects being nausea and vomiting and myelosuppression. One death may have been drug related. Methotrexate displays minimal clinical activity in patients with advanced or recurrent endometrial carcinoma who have received no prior chemotherapy.

AB - Thirty-three patients with advanced or metastatic endometrial carcinoma were entered in a Phase II trial utilizing methotrexate, 40 mg/m2 intravenously on a weekly basis. Almost all patients had prior total abdominal hysterectomy and almost two-thirds prior pelvic irradiation. No patient had prior chemotherapy. There was one complete and one partial response, for a complete and partial response rate of 6% (95% confidence intervals for a response of 1.7 to 19.6%). Toxicity was mild, with major adverse effects being nausea and vomiting and myelosuppression. One death may have been drug related. Methotrexate displays minimal clinical activity in patients with advanced or recurrent endometrial carcinoma who have received no prior chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0025260439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025260439&partnerID=8YFLogxK

M3 - Article

C2 - 2407104

AN - SCOPUS:0025260439

VL - 13

SP - 61

EP - 63

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -